The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction
Open accessAbstract
Background: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI). Methods: We randomized 1601 patients with recent acute MI to oral asundexian 10, 20, or 50 mg or placebo once daily for 6 to 12 months in a double-blind, placebo-controlled, phase 2, dose-ranging trial. Patients were randomized within 5 days of their qualifying MI and received dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor. The effect of asundexian on FXIa inhibition was assessed at 4 weeks. The prespecified main safety outcome was Bleeding Academic Research Consortium type 2, 3, or 5 bleeding comparing all pooled asundexian doses with placebo. The prespecified efficacy outcome was a composite of cardiovascular death, MI, stroke, or stent thrombosis comparing pooled asundexian 20 and 50 mg doses with placebo. Results: The median age was 68 years, 23% of participants were women, 51% had ST-segment–elevation MI, 80% were treated with aspirin plus ticagrelor or prasugrel, and 99% underwent percutaneous coronary intervention before randomization. Asundexian caused dose-related inhibition of FXIa activity, with 50 mg resulting in >90% inhibition. Over a median follow-up of 368 days, the main safety outcome occurred in 30 (7.6%), 32 (8.1%), 42 (10.5%), and 36 (9.0%) patients receiving asundexian 10 mg, 20 mg, or 50 mg, or placebo, respectively (pooled asundexian versus placebo: hazard ratio, 0.98 [90% CI, 0.71–1.35]). The efficacy outcome occurred in 27 (6.8%), 24 (6.0%), 22 (5.5%), and 22 (5.5%) patients assigned asundexian 10 mg, 20 mg, or 50 mg, or placebo, respectively (pooled asundexian 20 and 50 mg versus placebo: hazard ratio, 1.05 [90% CI, 0.69–1.61]). Conclusions: In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events. These data support the investigation of asundexian at a dose of 50 mg daily in an adequately powered clinical trial of patients who experienced acute MI. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04304534; URL: https://www.clinicaltrialsregister.eu/ctr-search/search ; Unique identifier: 2019-003244-79.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationTicagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438 · cited 1×
“The overall median (25th, 75th percentile) time from randomization to stent thrombosis was 47 (7, 134) days.”
BackgroundSelf-citation
Metadata
- Authors
- Rao, S. V., Kirsch, B., Bhatt, D. L., Budaj, A., Coppolecchia, R., Eikelboom, J., James, S. K., Jones, W. S., Merkely, B., Keller, L., Hermanides, R. S., Campo, G., Ferreiro, J. L., Shibasaki, T., Mundl, H., Alexander, J. H., Hengstenberg, C., Steinwender, C., Alber, H., Steringer-Mascherbauer, R., Schober, A., Auer, J., Roithinger, F. X., von Lewinski, D., Moertl, D., Huber, K., Coussement, P., Hoffer, E., Beauloye, C., Janssens, L., Vranckx, P., De Raedt, H., Vanassche, T., Vrolix, M., Rokyta, R., Parenica, J., Pelouch, R., Motovska, Z., Alan, D., Kettner, J., Polasek, R., Cermak, O., Sedlon, P., Hanis, J., Novak, M., Belohlavek, J., Horacek, T., Leggewie, S., Wenzel, P., vom Dahl, J., Sievers, B., Pulz, J., Schellong, S., Clemmensen, P., Muller-Hennessen, M., Rassaf, T., Falukozi, J., Ruzsa, Z., Tomcsanyi, J., Csanadi, Z., Herczeg, B., Koszegi, Z., Vorobcsuk, A., Kiss, R., Baranyai, C., Dezsi, C., Merkely, B., Lupkovics, G., Rossini, R., Scherillo, M., Sergio Saba, P., Calogero Campo, G., Calo, L., Nassiacos, D., Quadri, G., Sciahbasi, A., Silvio Marenzi, G. C., Reimers, B., Perna, G. P., Sacca, S., Fattore, L., Brunelli, C., Picchi, A., Kuramochi, T., Kondo, K., Aoyama, T., Kudoh, T., Yamamoto, T., Takaya, T., Mukai, Y., Fukui, K., Morioka, N., Ando, K., Yamamuro, A., Morita, Y., Koga, Y., Watanabe, T., Sakamoto, T., Shibasaki, T., Maebuchi, D., Takahashi, A., Yonetsu, T., Kakuta, T., Nishina, H., Oemrawsingh, R., Dorman, R., Oude Ophius, T., Prins, P., al Windy, N. Y. Y., Zoet-Nugteren, S. K., Hermanides, R., van Eck, M., Scherptong, R., Cornel, J. H., Damman, P., Bech, G., Torquay, R., Kietselaer, B., Grzelakowski, P., Krzysztof, D., Budaj, A., Miekus, P., Przybylski, A., Zarebinski, M., Balsam, P., Szachniewicz, J., Gierlotka, M., Tycinska, A., Iniguez Romo, A., Fernandez Ortiz, A., Carrasquer Cucarella, A., Sanmartin Fernandez, M., Sionis, A., Bueno Zamora, H., Ferreiro Gutierrez, J. L., Almenar, L., Ferreira Gonzalez, I., Pascual Figal, D. A., Almendro Delia, M., Jimenez Fernandez, M., Skeppholm, M., Zedigh, C., Angeras, O., Lauermann, J., Erlinge, D., Gustafsson, R., Mooe, T., Utreras, A., James, S., Grimfjard, P., Pedrazzini, G., Mach, F., Fournier, S., Haegeli, L., Beer, J. H., Leibundgut, G., Kobza, R., Kaiser, C., Kunadian, V., Al-Lamee, R., Gorog, D., Khan, S., Trevelyan, J., Toor, I., Smith, J., Purushottam, B., Treasure, C., Arena, F., Vedere, A., Henderson, D., Gilani, S., Jones, A., Carrillo-Jimenez, R., Gillespie, E., Marhefka, G., Wang, D., Olson, C., Bloom, S., Iftikhar, F., Brabham, D., McGinty, J., Thompson, C., Talano, J., Ginete, W., Williams, M., Masud, A., Ariani, M., Bitar, F., Wang, T., & Samuelson, B.
- Venue
- Circulation
- Published
- 2022-10-18
- Volume
- 146
- Issue
- 16
- Pages
- 1196-1206
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W4293410865
- Cited by
- 158
- References
- 5
- FWCI
- 21.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. https://app.cochat.ai/papers/10.1161/circulationaha.122.061612
- The paper
- Rao, S. V., Kirsch, B., Bhatt, D. L., Budaj, A., Coppolecchia, R., Eikelboom, J., James, S. K., Jones, W. S., Merkely, B., Keller, L., Hermanides, R. S., Campo, G., Ferreiro, J. L., Shibasaki, T., Mundl, H., Alexander, J. H., Hengstenberg, C., Steinwender, C., Alber, H., . . . Samuelson, B. (2022). A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation. https://doi.org/10.1161/circulationaha.122.061612
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.